Overview

• Foghorn Therapeutics Q3 collaboration revenue rises, driven by Lilly partnership

• Net loss for Q3 decreases compared to last year

• Company maintains strong cash position with runway into 2028

Outlook

• Foghorn expects selective CBP degrader to be IND-ready in 2026

• Company anticipates IND-enabling studies for EP300 degrader in 2026

• Foghorn projects ARID1B degrader in vivo proof of concept in 2026

Result Drivers

• LILLY COLLABORATION - Ongoing collaboration with Lilly drives advancement of novel oncology medicines, including FHD-909 program

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $11.50, about 69.3% above its November 4 closing price of $3.53

Press Release: ID:nGNXbvYtKl

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)